Skip to Content
Merck
CN

F8927

Flupirtine maleate salt

≥98% (HPLC)

Synonym(s):

2-Amino-6-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]-carbamic acid ethyl ester maleate salt

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C15H17FN4O2 · C4H4O4
CAS Number:
75507-68-5
Molecular Weight:
420.39
NACRES:
NA.77
PubChem Substance ID:
24278445
UNSPSC Code:
12352200
MDL number:
MFCD00941415

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Flupirtine maleate salt, ≥98% (HPLC)

InChI key

DPYIXBFZUMCMJM-BTJKTKAUSA-N

SMILES string

OC(=O)\C=C/C(O)=O.CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)nc1N

InChI

1S/C15H17FN4O2.C4H4O4/c1-2-22-15(21)19-12-7-8-13(20-14(12)17)18-9-10-3-5-11(16)6-4-10;5-3(6)1-2-4(7)8/h3-8H,2,9H2,1H3,(H,19,21)(H3,17,18,20);1-2H,(H,5,6)(H,7,8)/b;2-1-

assay

≥98% (HPLC)

form

solid

color

white

solubility

DMSO: soluble >20 mg/mL
H2O: insoluble

storage temp.

2-8°C

Quality Level

100

Biochem/physiol Actions

Flupirtine is commercially available as maleate salt. It exists in two polymorphs : flupirtine maleate A and B. Flupirtine is useful in treating muscular spasm, muscle tension and muscle stiffness. It is known to be effective in relieving back pain. Along with cytoprotection, flupirtine also offers protection against neurodegenerative disorders such as multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer′s disease, Parkinson′s disease, Huntington′s chorea and AID (acquired immunodeficiency) associated encephalopathy. Flupirtine is found to be a potential drug for eye-related problems like maculopathy including diabetic retinopathy, retinitis pigmentosa and glaucoma. It is also proved to be helpful in preventing cardiac associated disorders such as myocardial ischemia and infarction, cerebral ischemia and infarction. Hepatitis is also prevented by the use of flupirtine.
Non-opioid analgesic; cytoprotective versus PrP fragment 106-126

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000507068
0000507067
0000507067
0000507068
0000423902

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Syed Mohammed Naser et al.
Journal of the Indian Medical Association, 110(3), 158-160 (2012-10-04)
The study was conducted to evaluate the efficacy and safety of flupirtine maleate 100 mg thrice daily compared to tramadol hydrochloride 50 mg thrice daily as postoperative pain management for 5 days. A total of 113 postoperative patients were recruited
Fang Yu et al.
Epilepsy research, 97(1-2), 64-72 (2011-08-13)
Activation of KCNQ-channels has been shown to decrease or reduce the propagation of neuronal excitation in the immature central nervous system, and KCNQ activators represent a new class of anticonvulsant compounds. Their effectiveness has been demonstrated in many seizure models
Martin C Michel et al.
British journal of clinical pharmacology, 73(5), 821-825 (2011-11-03)
To determine efficacy of the analgesic flupirtine in the treatment of overactive bladder syndrome in a proof-of-concept study. Double-blind, double-dummy, three-armed comparison of flupirtine extended release (400 mg/day, titrated to 600 mg/day), tolterodine extended release (4 mg/day) and placebo for
Felicia Klinger et al.
British journal of pharmacology, 166(5), 1631-1642 (2011-12-23)
Flupirtine is a non-opioid analgesic that has been in clinical use for more than 20 years. It is characterized as a selective neuronal potassium channel opener (SNEPCO). Nevertheless, its mechanisms of action remain controversial and are the purpose of this
Anton Kolosov et al.
Pain medicine (Malden, Mass.), 13(11), 1444-1456 (2012-10-20)
Current treatments for cancer pain are often inadequate, particularly when metastasis to bone is involved. The addition to the treatment regimen of another drug that has a complementary analgesic effect may increase the overall analgesia without the necessity to increase
View All Related Papers

Related Content

Data Sheet - F8927

Instructions

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service